Preliminary evaluation of potential anti-epileptic drugs by single dose electrophysiological and pharmacological studies in patients.

In phase 1 evaluation of potential anti-epileptic drugs (AEDs), insufficient attention has perhaps been directed to the transition from single, and multi-dose studies in normal volunteers to clinical trials of some weeks duration in patients. Acute single dose studies in epileptic patients already receiving AEDs may reduce avoidable errors in early controlled trials. Acute single dose studies provide the opportunity of obtaining some preliminary evidence of efficacy by observing the effects of the drug on quantified epileptiform EEG discharges, both those occurring spontaneously in long term telemetric recordings and those elicited by standardised photic stimulation in susceptible subjects. The pharmacokinetics of the new drug may be profoundly influenced by the comedication (as illustrated by lamotrigine, the half life of which varies by a factor of 10 depending on comedication). Conversely, the new drug may so influence metabolism of the comedication that the results of add-on trials may be virtually uninterpretable, unless steps are taken to maintain blood levels of the other AEDs. A method of addressing this problem is illustrated in the case of an imidazole, R57720. Adverse experiences may also occur more readily when a new drug is added to comedication than when it is given to normal volunteers and these problems in chronic trials can be anticipated from acute studies.